A carregar...
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells
BACKGROUND: Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. Since the in vivo efficacy of this class...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3852167/ https://ncbi.nlm.nih.gov/pubmed/24053678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-14-47 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|